查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988397

鼻塞緩解藥物市場：2026-2032 年全球市場預測，按產品類型、給藥途徑、處方狀態、劑型、分銷管道和最終用戶分類。

Decongestant Market by Product Type, Route Of Administration, Prescription Status, Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鼻塞緩解藥物市場價值將達到 74.8 億美元，到 2026 年將成長至 79.6 億美元，到 2032 年將達到 125.9 億美元，年複合成長率為 7.72%。

主要市場統計數據
基準年 2025 74.8億美元
預計年份：2026年 79.6億美元
預測年份 2032 125.9億美元
複合年成長率 (%) 7.72%

對不斷發展的鼻塞生態系統進行簡要概述，重點關注需要經營團隊關注的臨床、監管和商業性趨勢。

鼻塞緩解藥物市場格局正迅速變化，其促進因素包括消費者行為的轉變、監管機構對安全性的日益重視以及醫療服務管道的演變。本執行摘要概述了影響產品開發和商業化的關鍵主題促進因素，並為後續章節提供了框架，這些章節檢驗結構性變化、關稅影響、市場細分洞察、區域趨勢和競爭對手動態。本報告旨在引導企業主管了解近期將影響產品生命週期、供應鏈和分銷策略的關鍵因素。

產品創新、監管加強以及分銷管道數位化如何重塑整個鼻塞治療行業的競爭和商業策略。

在技​​術創新、患者期望和醫療保健系統優先事項相互作用的背景下，鼻塞緩解藥物市場正在經歷變革。首先，劑型創新正在改變市場競爭動態。定量滴鼻劑和單劑量鼻噴劑技術的進步，實現了差異化的安全性，並提高了給藥的精確度。同時，數位醫療的整合加速了電子處方箋和線上藥局管道的普及，進而影響了包裝、病患教育和上市後監測等方面的要求。

2025 年關稅變動對鼻塞藥物生產供應鏈韌性、籌資策略與商業定價結構的連鎖反應。

美國2025年宣布的關稅調整將產生一系列累積效應，影響原料採購、成品定價和供應商選擇。對於依賴跨境進口藥品活性成分和包裝組件的製造商而言，關稅調整將加劇其成本結構。因此，採購團隊被迫重新評估供應商組合，加快替代供應商的認證，並重新談判供應契約，以確保其毛利率。

一個多層次細分框架，解釋了產品形式、管理途徑、通路和最終用戶目標如何影響策略優先順序。

為了深入了解市場動態，有必要考慮多種細分框架，這些框架定義了產品性能和客戶參與。根據產品類型，市場細分為滴鼻劑、鼻噴霧和片劑/膠囊劑。眼藥水類別進一步細分為多劑量型和單劑量型，鼻噴霧類別細分為定量噴霧型和標準噴霧型，藥片/膠囊類別細分為緩釋型和速效型，所有這些細分都會影響配方選擇、包裝設計和使用說明。根據給藥途徑，市場被分類為“鼻內”和“口服”，並重點關注影響臨床實踐建議的具體臨床考慮、預期效果和患者偏好因素。

針對鼻塞緩解藥物產業的區域比較策略指南，平衡全球平台的效率與當地法規、付款者和分銷管道的實際情況。

區域趨勢差異顯著，需要在不同的監管、付款方和分銷環境中製定量身定做的策略才能取得成功。美洲地區的特點是特定司法管轄區的監管審查嚴格，擁有成熟的非處方藥 (OTC) 生態系統和成熟的零售藥店網路，品牌忠誠度和銷售點陳列仍然具有重要影響。同時，歐洲、中東和非洲 (EMEA) 地區的法規環境更為分散，這不僅為差異化的核准策略和跨境分銷解決方案帶來了挑戰，也帶來了機會。在地化的標籤和藥物安全監測計畫通常會影響產品進入市場的速度。

產業先驅如何將配方開發、供應鏈韌性和全通路客戶參與相結合，以確保永續的競爭優勢。

鼻塞緩解領域的主要企業正著力採取一系列策略舉措，重點在於整合產品開發、柔軟性分銷和循證實踐。一些企業正投資於改進配方和給藥技術，以在安全性和起效速度方面脫穎而出；而另一些企業則優先考慮最佳化標籤和生命週期管理，以延長產品的效用。同時，製藥公司與數位藥局平台之間的合作也日益普遍，旨在最佳化患者用藥途徑、提高用藥依從性並收集真實世界數據（REW）。

透過供應鏈多元化、創新和全通路部署，採取高影響力策略措施，幫助製造業確保韌性並加速產品推廣。

產業領導企業應採取一系列優先措施，以保護利潤率、加快產品滲透並降低監管風險。首先，他們應實現供應商多元化，並加強供應商合格流程，以降低關稅衝擊和單一來源供應中斷帶來的風險，同時投資於基於情境的服務成本模型，為定價和合約談判決策提供依據。其次，他們應加快在能夠展現臨床差異化優勢並具有市場可信度的領域進行配方重新設計和給藥方式創新方面的投資，以期提高關鍵終端用戶群體的安全性和便利性。

結合專家訪談、監管分析和情境測試的透明混合方法，有助於得出可操作的結論。

本研究整合了主要定性研究結果和二手數據，以得出基於證據且可操作的結論。主要研究包括對相關人員（如製劑科學家、法規官員、採購主管和藥局經理）進行結構化訪談，以及組織專家小組對研究結果檢驗。二手資料包括監管指導文件、關於減充血劑藥理學和安全性的臨床文獻、專利趨勢回顧以及揭示企業策略和供應鏈結構的公開文件。

為確保鼻塞緩解市場的長期韌性和商業性意義，高階主管應實施綜合洞察和策略重點。

總而言之，這些分析表明，鼻塞緩解市場的成功取決於整合科學、供應鏈和商業性執行的綜合策略。簡而言之，那些投資於管理系統創新、建立穩健且多元化的供應鏈網路，並將全通路分銷與引人入勝的患者教育相結合的企業，將更有能力應對日益成長的監管壓力和關稅。相反，那些孤立地應對這些挑戰的企業，則可能面臨利潤率下降和新產品及改良產品市場滲透速度減慢的風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：鼻塞緩解藥物市場：依產品類型分類

  • 滴鼻劑
    • 多次給藥
    • 單一劑量
  • 鼻噴霧
    • 計量噴霧型
    • 標準噴霧
  • 片劑和膠囊
    • 緩釋
    • 立即生效

第9章：鼻塞緩解藥物市場：依給藥途徑分類

  • 鼻腔
  • 口服

第10章：鼻塞緩解藥物市場：依處方狀態分類

  • 非處方藥
  • 處方箋

第11章：鼻塞緩解藥物市場：依劑型分類

  • 液體
    • 懸浮液
    • 糖漿
  • 半固態
    • 凝膠
    • 軟膏
  • 固態的
    • 膠囊
    • 藥片

第12章：鼻塞緩解藥物市場：依分銷管道分類

  • 醫院藥房
    • 私人的
    • 一般的
  • 網路藥房
    • 品牌官方網站
    • 第三方平台
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第13章：鼻塞緩解藥物市場：依最終用戶分類

  • 成人
  • 老年人
  • 小兒科
    • 青年
    • 兒童
    • 嬰兒

第14章：鼻塞緩解藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：鼻塞緩解藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：鼻塞緩解藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國：鼻塞緩解藥物市場

第18章 中國：鼻塞緩解藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alcon
  • Aptar Pharma
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Church & Dwight Co., Inc.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Haleon Group of Companies
  • Johnson & Johnson Services, Inc.
  • Perrigo Company PLC
  • Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Boots Company PLC
  • Viatris, Inc.
  • Walgreen Co.
Product Code: MRR-4A6A214484D8

The Decongestant Market was valued at USD 7.48 billion in 2025 and is projected to grow to USD 7.96 billion in 2026, with a CAGR of 7.72%, reaching USD 12.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.48 billion
Estimated Year [2026] USD 7.96 billion
Forecast Year [2032] USD 12.59 billion
CAGR (%) 7.72%

A concise orientation to the evolving decongestant ecosystem highlighting clinical, regulatory, and commercial signals that demand executive attention

The decongestant landscape is undergoing rapid change driven by shifts in consumer behavior, regulatory emphasis on safety, and evolving channels of care delivery. This executive summary introduces key thematic drivers shaping product development and commercialization, and it frames the subsequent sections that examine structural shifts, tariff implications, segmentation intelligence, regional dynamics, and competitive behavior. The goal here is to orient senior decision-makers to the major forces that will affect product lifecycles, supply chains, and distribution strategies over the near term.

To provide immediate relevance for strategy discussions, the analysis synthesizes clinical, regulatory, and commercial signals that matter to manufacturers, distributors, and healthcare providers. It emphasizes where margin pressure may emerge, the role of differentiation through formulation and delivery technology, and the strategic responses that successful organizations are employing. By focusing on actionable insights, this introduction sets expectations for how the remainder of the document deepens understanding and supports priority-setting for executives and functional leaders.

How product innovation, regulatory tightening, and channel digitization are reshaping competitive and commercial strategies across the decongestant sector

The decongestant market is experiencing transformative shifts as technological innovation, patient expectations, and health system priorities converge. First, delivery format innovation is altering competitive dynamics; advances in metered-dose nasal sprays and single-dose drop technologies are enabling differentiated safety profiles and improved dosing accuracy. At the same time, digital health integration is accelerating adoption of e-prescribing and online pharmacy channels, which in turn influences packaging, patient education, and post-market surveillance requirements.

In parallel, regulatory scrutiny and pharmacovigilance practices are tightening around systemic exposure and adverse event reporting, prompting manufacturers to invest in reformulation and bioavailability studies. Moreover, consumer preferences are trending toward convenience and transparency, with over-the-counter positioning and clear labeling becoming pivotal in retail decision-making. Consequently, companies must reconcile R&D investments, regulatory pathways, and omnichannel distribution plans to maximize product uptake and minimize compliance risk. These shifts collectively signal that incremental product changes are insufficient; instead, firms need coordinated strategies across scientific, commercial, and regulatory functions to capitalize on emerging opportunities.

The downstream effects of 2025 tariff changes on supply chain resilience, procurement strategy, and commercial pricing structures in decongestant manufacturing

United States tariff adjustments announced for 2025 introduce a set of cumulative effects that influence raw material sourcing, finished-goods pricing, and supplier selection. Tariff rebalancing has a magnifying effect on cost structures for manufacturers that rely on cross-border inputs for active pharmaceutical ingredients and packaging components. As a result, procurement teams are being forced to reevaluate supplier portfolios, accelerate qualification of alternative vendors, and renegotiate supply agreements to protect gross margins.

Beyond direct cost implications, tariffs create strategic incentives for reshoring and regionalization of manufacturing capacity, particularly for higher-value formulations and controlled delivery systems. This trend is accompanied by increased capital allocation toward supply continuity measures, such as dual-sourcing strategies and buffer inventory for critical components. In addition, price pressures at the wholesale level cascade to distribution partners and, in some cases, influence formulary positioning and reimbursement discussions. Taken together, the tariff environment is prompting a more holistic approach to cost-to-serve modeling, requiring coordination among procurement, regulatory, and commercial teams to manage both price and access outcomes.

A layered segmentation framework explaining how product form, administration route, distribution pathways, and end-user cohorts drive strategic prioritization

A granular view of market dynamics requires attention to multiple segmentation frameworks that define product performance and customer interactions. Based on Product Type, market is studied across Drops, Nasal Sprays, and Tablets & Capsules and the Drops category is further analyzed across Multi Dose and Single Dose while the Nasal Sprays category is further analyzed across Metered Dose and Standard Spray and the Tablets & Capsules category is further analyzed across Extended Release and Immediate Release, which informs formulation choices, packaging design, and user instructions. Based on Route Of Administration, market is studied across Nasal and Oral, highlighting distinct clinical considerations, onset of action expectations, and patient preference drivers that influence point-of-care recommendations.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies and the Hospital Pharmacies segment is further analyzed across Private and Public while the Online Pharmacies segment is further analyzed across Branded Websites and Third-Party Platforms and the Retail Pharmacies segment is further analyzed across Chain Pharmacies and Independent Pharmacies, clarifying where channel economics and regulatory controls differ. Based on End User, market is studied across Adults, Geriatric, and Pediatrics and the Pediatrics segment is further analyzed across Adolescents, Children, and Infants, which impacts labeling, dosing forms, and caregiver communication strategies. Based on Prescription Status, market is studied across Over The Counter and Prescription, underlining how regulatory pathways and marketing permissions shape available promotion levers. Based on Form, market is studied across Liquid, Semi Solid, and Solid and the Liquid category is further analyzed across Suspension and Syrup while the Semi Solid category is further analyzed across Gel and Ointment and the Solid category is further analyzed across Capsule and Tablet, informing manufacturing investments and shelf-life trade-offs. Interpreting these segmentation layers together helps teams prioritize portfolio development and channel investments based on clinical positioning, regulatory constraints, and patient-centric design considerations.

Comparative regional playbooks for the decongestant sector that reconcile global platform efficiencies with local regulatory, payer, and channel realities

Regional dynamics vary significantly and require tailored strategies to succeed across distinct regulatory, payer, and channel environments. The Americas region is characterized by high regulatory scrutiny in certain jurisdictions, established over-the-counter ecosystems, and a mature retail pharmacy footprint where brand loyalty and point-of-sale placement remain influential. Meanwhile, in Europe, Middle East & Africa the regulatory mosaic is more fragmented across countries, presenting both barriers and opportunities for differentiated registration strategies and cross-border distribution solutions; localized labeling and pharmacovigilance programs frequently determine the speed of market entry.

In the Asia-Pacific region, growth vectors are often driven by rapid urbanization, expanding e-commerce adoption, and diverse healthcare access models that require nimble channel strategies. Consequently, product formats that emphasize convenience and patient education tend to achieve faster uptake in urban centers, whereas stable, long-shelf-life formulations resonate in areas with limited cold-chain infrastructure. Given these contrasts, regional playbooks should balance global platform efficiencies with local adaptation, aligning manufacturing footprints, regulatory dossiers, and marketing messages to the specific attributes of each geography.

How industry frontrunners are aligning formulation, supply chain resilience, and omnichannel engagement to secure sustainable competitive advantage

Leading companies in the decongestant space are converging on a set of strategic behaviors that emphasize integrated product development, distribution flexibility, and evidence generation. Several organizations are investing in formulation upgrades and delivery technologies to differentiate on safety and onset of action, while others are prioritizing label expansions and lifecycle management to extend product relevance. At the same time, partnerships between manufacturers and digital pharmacy platforms are becoming more common as firms seek to optimize patient access, adherence support, and real-world evidence collection.

Competitive positioning increasingly reflects sophistication in supply chain planning and regulatory strategy. Firms that proactively manage ingredient sourcing, regulatory filings, and pharmacovigilance demonstrate greater resilience to both policy shifts and demand fluctuations. In addition, companies that cultivate direct-to-consumer education programs and omnichannel sales capabilities are better positioned to capture shifts from traditional retail to online procurement. Overall, the competitive landscape rewards organizations that integrate scientific rigor with commercial agility and an explicit focus on end-user needs.

High-impact strategic moves for manufacturers to secure resilience and accelerate adoption through supply diversification, innovation, and omnichannel execution

Industry leaders should adopt a set of prioritized actions that protect margin, accelerate product uptake, and mitigate regulatory risk. First, strengthen supplier diversification and qualification processes to reduce exposure to tariff shocks and single-source disruptions, while concurrently investing in scenario-based cost-to-serve models that inform pricing and contractual levers. Second, accelerate reformulation and delivery innovation investments where clinical differentiation can be demonstrated and marketed credibly, with the goal of improving safety profiles and convenience for key end-user cohorts.

Third, expand omnichannel capabilities by integrating online pharmacy partnerships with brick-and-mortar distribution plans and tailored patient support programs; this will improve access while generating richer adherence and outcomes data. Fourth, enhance regulatory and pharmacovigilance functions to shorten approval timelines for label changes and to proactively manage safety communications. Finally, align commercial incentives across sales, medical affairs, and supply chain teams to ensure coordinated execution, faster response to market signals, and better stewardship of promotional resources.

A transparent mixed-methods approach combining expert interviews, regulatory analysis, and scenario testing to underpin actionable conclusions

This research synthesizes primary qualitative insights with secondary data streams to produce evidence-based, action-oriented conclusions. Primary research comprises structured interviews with industry stakeholders including formulation scientists, regulatory affairs leaders, procurement executives, and pharmacy directors, combined with targeted expert panels to validate interpretive findings. Secondary inputs include regulatory guidance documents, clinical literature relating to decongestant pharmacology and safety, patent landscape reviews, and public filings that illuminate corporate strategy and supply chain arrangements.

Analytical methods integrate thematic coding of qualitative interviews, cross-validation of regulatory trends against published guidance, and scenario analysis to test the resilience of supply chain and pricing strategies under tariff and policy permutations. Throughout the process, methodological rigor was maintained through source triangulation and transparent documentation of assumptions so that users can trace how specific conclusions were derived and apply the approach to internal decision models.

Consolidated implications and strategic priorities that executives must act on to secure long-term resilience and commercial relevance in the decongestant space

The cumulative analysis reveals that success in the decongestant market will hinge on integrated strategies that bridge science, supply chain, and commercial execution. In short, organizations that invest in delivery system innovation, build resilient and diversified supply networks, and align omnichannel distribution with compelling patient education will be best positioned to navigate regulatory tightening and tariff-driven cost pressures. By contrast, firms that treat these challenges in isolation risk erosion of margin and slower adoption of new or reformulated products.

Looking ahead, coordination across functions-R&D, regulatory, procurement, and commercial-will be a defining competency. Stakeholders should prioritize initiatives that deliver measurable improvements in safety, convenience, and access, while maintaining flexibility to adapt to sudden policy changes. Ultimately, the synthesis underscores a pragmatic pathway: actionable, cross-functional programs grounded in evidence will yield sustainable advantage more reliably than incremental, siloed responses.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Decongestant Market, by Product Type

  • 8.1. Drops
    • 8.1.1. Multi Dose
    • 8.1.2. Single Dose
  • 8.2. Nasal Sprays
    • 8.2.1. Metered Dose
    • 8.2.2. Standard Spray
  • 8.3. Tablets & Capsules
    • 8.3.1. Extended Release
    • 8.3.2. Immediate Release

9. Decongestant Market, by Route Of Administration

  • 9.1. Nasal
  • 9.2. Oral

10. Decongestant Market, by Prescription Status

  • 10.1. Over The Counter
  • 10.2. Prescription

11. Decongestant Market, by Form

  • 11.1. Liquid
    • 11.1.1. Suspension
    • 11.1.2. Syrup
  • 11.2. Semi Solid
    • 11.2.1. Gel
    • 11.2.2. Ointment
  • 11.3. Solid
    • 11.3.1. Capsule
    • 11.3.2. Tablet

12. Decongestant Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
    • 12.1.1. Private
    • 12.1.2. Public
  • 12.2. Online Pharmacies
    • 12.2.1. Branded Websites
    • 12.2.2. Third-Party Platforms
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. Decongestant Market, by End User

  • 13.1. Adults
  • 13.2. Geriatric
  • 13.3. Pediatrics
    • 13.3.1. Adolescents
    • 13.3.2. Children
    • 13.3.3. Infants

14. Decongestant Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Decongestant Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Decongestant Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Decongestant Market

18. China Decongestant Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Alcon
  • 19.6. Aptar Pharma
  • 19.7. AstraZeneca PLC
  • 19.8. Aurobindo Pharma Limited
  • 19.9. Bausch Health Companies Inc.
  • 19.10. Bayer AG
  • 19.11. Boehringer Ingelheim International GmbH
  • 19.12. Church & Dwight Co., Inc.
  • 19.13. Cipla Ltd.
  • 19.14. Dr. Reddy's Laboratories Limited
  • 19.15. Eli Lilly and Company
  • 19.16. GlaxoSmithKline PLC
  • 19.17. Glenmark Pharmaceuticals Limited
  • 19.18. Haleon Group of Companies
  • 19.19. Johnson & Johnson Services, Inc.
  • 19.20. Perrigo Company PLC
  • 19.21. Procter & Gamble Company
  • 19.22. Reckitt Benckiser Group PLC
  • 19.23. Sanofi S.A.
  • 19.24. Sun Pharmaceutical Industries Limited
  • 19.25. Teva Pharmaceutical Industries Ltd.
  • 19.26. The Boots Company PLC
  • 19.27. Viatris, Inc.
  • 19.28. Walgreen Co.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DECONGESTANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DECONGESTANT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DECONGESTANT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DECONGESTANT MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DECONGESTANT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DECONGESTANT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DECONGESTANT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DECONGESTANT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DECONGESTANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DECONGESTANT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DECONGESTANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DECONGESTANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS DECONGESTANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL DECONGESTANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. GCC DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. GCC DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 289. GCC DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. GCC DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 292. GCC DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 293. GCC DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 294. GCC DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 295. GCC DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. GCC DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 297. GCC DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 298. GCC DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GCC DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 335. G7 DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 336. G7 DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. G7 DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 338. G7 DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 339. G7 DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 340. G7 DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 341. G7 DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 342. G7 DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 343. G7 DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 344. G7 DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 345. G7 DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 346. G7 DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 347. G7 DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 348. G7 DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 349. G7 DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 350. G7 DECONGESTANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. G7 DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2032 (USD MILLION)
  • TABLE 352. NATO DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 353. NATO DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. NATO DECONGESTANT MARKET SIZE, BY DROPS, 2018-2032 (USD MILLION)
  • TABLE 355. NATO DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 356. NATO DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 357. NATO DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 358. NATO DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 359. NATO DECONGESTANT MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 360. NATO DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 361. NATO DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2032 (USD MILLION)
  • TABLE 362. NATO DECONGESTANT MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 363. NATO DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 364. NATO DECONGESTANT MARKET S